NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis

Collegium Pharmaceutical, Inc. (COLL) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

COLL

$23.53

−$0.17 (−0.72%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare COLL with… →

COLL Key Statistics

As of Sep 4, 2026
Trading
Open
$23.54
Previous Close
$23.70
Day's Range
23.37–24.32
52-Week Range
23.37–50.79
Volume
900.80K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.72
Valuation
Market Cap
$729.41M
P/E Ratio
18.53
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
3.48
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.90
EPS (ttm)Profit attributable to each share over the last twelve months.
1.27
Financials (FY)
Revenue (FY)
$780.57M+23.62%
Net Income (FY)
$62.87M−9.13%
Profit marginThe share of revenue left as profit after all costs and taxes.
5.93%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
31.00M
1-Year Return
−40.02%
Dividend and dates
Earnings Date
November 5, 2026
Avg Volume
596.50K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

COLL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−49.18%
2025+61.61%
2024−6.92%
2023+32.67%
2022+24.20%
2021−6.74%
2020−2.67%
2019+19.86%
2018−6.99%
2017+18.56%
2016 (partial year)+29.32%

As of September 4, 2026.

COLL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$780.57M$62.87M8.1%
2024$631.45M$69.19M11.0%
2023$566.77M$48.16M8.5%
2022$463.93M−$25.00M−5.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$780.57M$463.26M$178.45M$62.87M8.1%
2024$631.45M$377.34M$166.98M$69.19M11.0%
2023$566.77M$326.17M$166.96M$48.16M8.5%
2022$463.93M$209.49M$33.32M−$25.00M−5.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

COLL Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricCOLLDrug Manufacturers - Specialty & Generic medianvs median
P/E18.5319.274% below
P/S ratio0.902.3061% below
Profit margin5.93%−3.14%9.1 pts above

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 8 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Collegium Pharmaceutical, Inc. (COLL) at $729.41M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 423.

Over the past 52 weeks the price has ranged from $23.37 to $50.79. COLL last closed at $23.53 on September 4, 2026. That is −$0.17 (−0.72%) against the previous close. The latest close sits 0.68% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $780.57M. Against the prior fiscal year total of $631.45M, that is a change of +23.62%. The same year closed with net income of $62.87M. That is −9.13% against the prior fiscal year. The reported profit margin is 5.93%. That is 9.1 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Trailing earnings per share are 1.27.

Across the 4 fiscal years on file, revenue moves from $463.93M in 2022 to $780.57M in 2025. Of those 4 years, 3 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 18.53 times earnings. That is 3.82% below the Drug Manufacturers - Specialty & Generic median of 19.27. The forward P/E on file is 3.48. Measured against sales, the shares trade at 0.9 times revenue. On price-to-sales that is 60.7% below the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

Over the trailing twelve months the price has returned −40.02%. Across 10 years the annualized return works out at +10.11%. The reported beta is 0.72. Daily returns over the trailing 10 years annualize to a volatility of 53.99%.

Growth & Income

No dividend is on file for COLL.

2026 is still running; the price is −49.18% year to date. Across the complete calendar years on file, 2025 returned +61.61% and 2018 returned −6.99%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Collegium Pharmaceutical, Inc. (COLL) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Collegium Pharmaceutical, Inc. COLL $729.41M 18.5
Takeda Pharmaceutical Company Limited TAK $58.92B —
Teva Pharmaceutical Industries Limited TEVA $42.37B 60.6
Haleon plc HLN $42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. Collegium Pharmaceutical, Inc. trades at a P/E of 18.5.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Visit website →